MAVENIR
21.5.2021 05:02:10 CEST | Business Wire | Press release
Mavenir, the Network Software Provider building the future of networks with cloud-native software that runs on any cloud and transforms the way the world connects, announced today that it’s working with National Telecom Public Company Limited (NT), a state-owned telecommunications company, 5GCT , a local partner specialized in delivering end-to-end 5G Smart Cities and Cisco Systems (Thailand), a leading networking company, to launch the first 5G Open RAN Smart City in Ban Chang, Thailand.
The launch of the 5G Smart City creates synergies between public and private sectors for a fully functional smart city. The city of Ban Chang, is connected to a motorway linking Thailand’s two largest cities: Pattaya and Bangkok. The location is within close proximity to U-Tapao International Airport, Map Ta Phut Industrial Zone and the new master planned Ban Chang Smart City that are strategically important infrastructure for the Digital Economy in Thailand and the Eastern Economic Corridor (EEC). These characteristics make Ban Chang the perfect city to take advantage of 5G use cases across industrial robots, factory automation, remote telemedicine, aviation, logistics and agriculture. Industry leaders are terming the development the ‘Silicon Beach ’ of Asia.
The Ban Chang Smart City 5G Private Network operates on Millimeter wave (mmWave) spectrum, spectrum which is ideally suited for a network operating Internet of Thing (IoT) sensors, drones and smart poles, all applications which require fast data uplink to the core for realtime analysis and city management.
Mavenir provided a cloud-native, open architecture-based Private Network solution that enabled TOT1 to reach the promise of 5G. The software-based platform enabled the transformation of the mobile communication private network into a completely virtualized environment, where devices, applications, and services run on an automated network using open architecture, containers, and artificial intelligence (AI). Mavenir’s end-to-end 5G Open RAN, Millimeter wave (mmWave) radios and 5G Core with Open API technology standards, in-sync with the cloud-native solutions supporting private On-Premise applications delivers Smart City concepts such as real-time diagnostics of traffic, public safety, digital signage and sensitive environmental conditions.
TOT’s IP transport infrastructure vendor and a key Mavenir technology partner, Cisco, provided switching hardware and application services to enable the ‘smart’ components of the 5G solution.
Mavenir’s Aniruddho Basu, GM of its Emerging Business Unit , said “We are proud to be part of this ambitious 5G project which sees a whole city connected on a series of 5G applications running in parallel. Connectivity is at the heart of this deployment - connecting people, communities, government services, and private sector services through local government data combined with new data acquired through Internet of Things (IOT), sensors, drones, and external collected data, to fully analyze it for proper city management and citizen knowledge.”
Commenting on the announcement, Shannon Kalayanamitr, Chief Executive Officer at 5GCT , said “At 5GTC, we are driven to strengthen the potential of Thailand through high speed 5G. The partnership with Mavenir as an infrastructure provider enables us to deliver robust, secure and reliable 5G Private Network infrastructure across enterprises, including smart city applications, industry 4.0 applications - automated industry and modern medicine.”
Taweewat Chantaraseno, Managing Director, Thailand & Indochina, Cisco Systems (Thailand), said “We are delighted to be part of the first 5G smart city in Thailand. With the partnership with Mavenir and Cisco Connected Communities Infrastructure (CCI), the host of Smart City can create a single, secure communications network to support all needs that are simpler to deploy and manage from end-to-end visibility, ranging from smart kiosks and outdoor Wi-Fi, to smart street lighting, parking, waste and more. Smart city infrastructure is enabling efficiency, cost reduction and improved living for city occupants and network infrastructure platform helps create these efficiencies.
About Mavenir:
Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry's only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers in over 120 countries, which serve more than 50% of the world’s subscribers.
Visit: www.mavenir.com
1 TOT and CAT Telecom recently merged under National Telecommunications Public Company Limited (NT) a Thai Government Telecom service provider
View source version on businesswire.com: https://www.businesswire.com/news/home/20210520005943/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fujirebio and Sysmex Begin Sales Collaboration for Dementia Testing5.2.2026 07:30:00 CET | Press release
Fujirebio Holdings, Inc. (HQ: Minato-ku, Tokyo; President & CEO: Goki Ishikawa; “Fujirebio”), a consolidated subsidiary of H.U. Group Holdings, Inc. (HQ: Minato-ku, Tokyo; Chairman, President and Group CEO: Shigekazu Takeuchi) and Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano, “Sysmex”) have agreed on a sales collaboration for dementia testing. This agreement follows continued discussions based on the Basic Agreement on Business Collaboration in the Field of Immunoassay concluded in October 2023.1 Sysmex will exclusively sell Fujirebio's fully automated Lumipulse® immunoassay systems and dementia-related reagents ("the Products") in regions and countries mutually agreed upon by both companies. Going forward, Fujirebio and Sysmex will collaborate to meet the growing testing needs accompanying the wider adoption of therapeutic drugs and will gradually expand the countries where the Products are sold. Since entering into the Basic Agreement on Business Collaboration in Octob
Invivoscribe® Launches LeukoStrat® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide5.2.2026 06:30:00 CET | Press release
Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat®KMT2A + MRD Assay and Software to its industry-leading oncology portfolio. The assay leverages digital PCR (dPCR) to support both screening and precise longitudinal MRD monitoring for KMT2A rearrangements in acute myeloid leukemia (AML) subjects. This quantitative test is currently available for research use in clinical trials and as a stand-alone kit for purchase by our global customers, and will soon be available as a service in our regional LabPMM® laboratories worldwide. The assay is available to detect key AML-associated KMT2A rearrangements, which account for the vast majority of KMT2A fusion partners in AML1 and those most commonly targeted in menin-inhibitor clinical development programs. Later this year, the assay will be enhanced with four additional KMT2A rearrangements which are frequently found in acute lymphocytic leukemia (ALL), expan
VeriSilicon Enhanced ISP8200-FS Series IP Achieves ASIL B Functional Safety Certification5.2.2026 01:00:00 CET | Press release
Enabling Next-Generation High-Performance Automotive Camera Systems VeriSilicon (688521.SH) today announced its latest enhanced versions of Image Signal Processing (ISP) IP ISP8200-FS series, ISP8200-ES and ISP8200L-ES, featuring improved performance and energy efficiency to better support complex automotive camera systems. These enhanced IPs have successfully achieved ISO 26262 ASIL B functional safety certifications issued by TÜV NORD, an international inspection and certification institution, further validating their suitability and reliability for ADAS and autonomous driving applications. The latest enhanced ISP8200-FS series IP can operate at up to 1.2 GHz and support data processing from up to 16 image sensors. It significantly improves the performance of multi-camera scheduling, enabling flexible data-access capabilities and efficient hardware pipeline utilization for automotive camera systems. The enhanced series IP integrates image processing technologies including Color Noise
Kinaxis Inc. to Host Fourth Quarter 2025 Financial Results Conference Call on March 5, 20264.2.2026 22:30:00 CET | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced that it has scheduled its conference call to discuss the financial results for its fourth quarter and year ended December 31, 2025. The call will be hosted on Thursday, March 5 at 8:30 a.m. Eastern Time by Razat Gaurav, chief executive officer, and Blaine Fitzgerald, chief financial officer, followed by a question and answer period. The Company will report its financial results for the fourth quarter and year after the close of markets on Wednesday, March 4, 2026. CONFERENCE CALL DETAILS DATE: Thursday, March 5, 2026 TIME: 8:30 a.m. Eastern Time WEBCAST: https://events.q4inc.com/attendee/567578009 (available for three months) About Kinaxis Kinaxis is a leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that
Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Blue Cross Blue Shield of North Dakota4.2.2026 22:30:00 CET | Press release
Mainstay Medical Holdings plc today announced that Blue Cross Blue Shield of North Dakota has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. The policy went into effect in January 2026 and specifies that ReActiv8 is the only therapy considered medically necessary by the policy when the conditions for coverage are met. “We are pleased that another Blue Cross Blue Shield payer has joined Anthem in making ReActiv8 available to well-selected patients after reviewing the large body of clinical evidence we have built,”said Jason Hannon, CEO of Mainstay Medical. “Patients with intractable chronic low back pain are desperately seeking durable solutions, and ReActiv8 has proven to be a safe and effective solution through six clinical studies with 633 patients treated and 1,950 patient-years of follow-up, including two multi-center, randomized controlled clinical studies. We look forward to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
